S
ince corticotropin-releasing factor (CRF) was isolated and characterized by Vale and co-workers (13) at the Salk Institute, peripheral cardiovascular actions of CRF have been observed across species ranging from rodents to humans. However, scientists have been perplexed by the relevance of these cardiovascular actions, since very low levels of CRF normally circulate in peripheral blood and relatively low levels of CRF gene expression are observed in the heart. It is well accepted that CRF is the primary hormone involved in the mammalian response to stress (2, 14) and produces central actions to increase blood pressure and stimulate pituitary adrenocorticotropic hormone (ACTH) and adrenal steroid release in all species studied. CRF belongs to a family of structurally related peptides that includes fish urotensin 1 and amphibian sauvagine, which also possess bioactivity similar to CRF in several mammalian systems. In 1993, the discovery of a high-affinity receptor for CRF (1) added to the acceptance of CRF as a physiologically relevant hormone present in the central nervous system and pituitary blood supply. However, lack of any significant expression of this CRF type 1 receptor (CRF-R1) in peripheral tissues relevant to control of the cardiovascular system did not support the hypothesis that circulating CRF may be directly controlling the heart or vasculature. In 1994, a second CRF receptor was cloned and characterized, and tissue expression of this type 2 receptor (CRF-R2) was reported soon thereafter. A splice variant of this type 2 receptor, CRF receptor type 2β (CRF-R2β), is present in both brain and peripheral tissues, including the heart, testis, and gastrointestinal tract. Recently, a third splice variant of the CRF-R2 was isolated, CRF-R2γ, and this receptor is expressed in human brain regions, including the hippocampus and septum (Fig. 1 ).
Isolation and characterization of urocortin
In 1995, Vaughan and colleagues (15) described the discovery of a CRF-related peptide expressed in rat brain known as urocortin (Ucn), named after its peptide homology to both the teleost hormone urotensin and to mammalian CRF and because it possesses biological activity exhibited by both of these peptides. Rat Ucn is a 40 amino acid peptide with 45% homology to rat/human CRF, 63% homology to teleost urotensin 1, and 35% homology to frog sauvagine ( Fig. 2 ) (15) . The urotensin-like immunoreactivity possessed by Ucn enabled its initial identification within a discrete region of the rat midbrain known as the Edinger-Westphal nucleus, a region that lacks expression of CRF mRNA. Ucn cDNA was isolated from an mRNA library derived from rat midbrain, which was screened with a urotensin probe. The full-length cDNA encodes a protein deduced to be 122 amino acids in length. The carboxy terminus contains Ucn, a putatively cleaved 40 amino acid peptide with a carboxy terminal amidation. Recently, the sequence of ovine Ucn was published and is identical to that for the rat peptide.
Vaughan and colleagues also reported Ucn to have marked cardiovascular actions in rats to lower blood pressure and increase heart rate, with a greater potency and duration of Notwithstanding this, the discovery of Ucn helped fill in the picture concerning potentially circulating CRF-like peptides acting as physiological regulators of regional hemodynamics, and subsequent studies in species such as sheep (9) have confirmed potent actions of Ucn on the heart and vasculature. Of significance, although CRF-R2α mRNA expression lies exclusively within the central nervous system, high levels of CRF-R2β mRNA exist within the cardiac atria and ventricles (myocardium, epicardium, arterioles) (10). Ucn is known to strongly bind and activate CRF-R2β receptors (15) , suggesting that there may now be an identified endogenous CRF-like peptide that binds to systemic receptors ( Fig. 1 ) and subsequently mediates cardiovascular effects in the periphery. We describe here some potential mechanisms of these hemodynamic effects.
Cardiovascular actions
CRF, sauvagine, and urotensin are known to produce potent effects on the cardiovascular system, effects that are dependent on whether the peptide is administered peripherally or directly into the central nervous system. Intravenous CRF is consistently seen to produce vasodilatation in rats, leading to a fall in blood pressure and reflex increase in heart rate, although this action is not observed in species such as sheep and only observed at relatively high concentrations in humans and monkeys. The rat and dog are the most responsive species to this vasodilator action, and these are the two species from which much of the early hemodynamic data on CRF has been obtained. In rats, intravenous CRF produces a peripheral vasodilator action predominantly mediated by a reduction in mesenteric arterial resistance (6, 8) . In contrast, in all species studied, including sheep, intracerebroventricular administration of CRF increases blood pressure, cardiac output, and heart rate. This effect is mediated by viscerotropic activation of sympathetic nervous outflow to raise peripheral resistance and heart rate in rats, dogs, and rabbits.
In rats, evidence that CRF or a related peptide may produce direct cardiac actions to increase contractility now exists from several in vitro studies. Grunt and co-workers (4) have shown that CRF perfused through isolated working rat hearts can increase both coronary blood flow and maximal aortic pressure, suggesting direct effects of CRF on cardiac activity. Neither the β-adrenergic receptor antagonist propranolol nor the nitric oxide synthesis inhibitor N G -nitro-L-arginine blocked these effects. Other studies have reported that CRF can directly increase the contractile force of isolated guinea pig ventricular myocardium, independent of norepinephrine release or Na (5) have demonstrated that CRF and related peptides can directly stimulate cAMP accumulation in isolated neonatal rat cardiomyocytes.
Intravenous injection of CRF in conscious sheep promotes little change in mean arterial pressure, heart rate, or cardiac output. Most notably, there is no change in cardiac contractility (9) . However, a robust increase in plasma ACTH and cortisol levels is observed. This lack of any significant peripheral hemodynamic action of CRF in sheep may be due to species differences in binding of CRF to peripheral CRF-R2. It is possible that ovine CRF is highly specific for type 1 receptors within the brain and pituitary and lacks any significant binding and activation of ovine cardiac type 2 receptors.
Ucn itself has been shown to possess potent and long-lasting hypotensive actions in conscious rats, as reported by Vale's group in 1995 (15) . Ucn produced a dose-dependent hypotension, and CRF showed ~30% of the hypotensive potency of Ucn. The duration of hypotensive action of Ucn in rats was almost 2 h, with that of CRF being <1 h. Increases in heart rate, probably partly baroreflex mediated, were associated with these blood pressure changes. The mechanism of this hypotension following Ucn injection might presumably be via a peripheral vasodilator action, possibly due to a specific action on mesenteric vascular beds, as described for CRF, sauvagine, and urotensin. We have recently observed in anesthetized rats that intravenous Ucn can reduce arterial pressure, aortic flow, stroke volume, and aortic resistance, together with an increase in heart rate and aortic conductance, suggesting that Ucn does indeed act to produce peripheral vasodilatation in rats. Interestingly, we also observed a 50% increase in maximum aortic flow and a 90% increase in aortic flow rate, two indicators of cardiac contractility; hence Ucn does appear to have positive cardiac inotropic actions in anesthetized rats. Spina and coworkers have reported that Ucn injected into the lateral cerebral ventricles in rats increases blood pressure slightly (11); however, there was no change in myocardial contractility. This further supports the concept that the cardiac inotropic action of Ucn may be mediated by a peripheral action, probably directly on the heart. A recent study in isolated rat hearts has indeed observed direct actions of Ucn to induce a positive inotropic action (12) , in addition to a reduction in coronary artery perfusion pressure (resistance). The inotropic action was dependent on an intact cyclooxygenase/prostaglandin synthesis pathway and was unaffected by inhibitors of nitric oxide production.
Our study in conscious sheep investigated in detail the cardiovascular actions of rat/ovine Ucn (9), and Fig. 3 compares these effects to those observed in rats. Ucn produced a slowly developing increase in mean arterial pressure that was associated with a rise in heart rate and in cardiac output.
The most striking cardiovascular change seen with intravenous Ucn in sheep was a rapid and extremely potent increase in cardiac contractility, as reflected by the large increases in both maximum aortic flow and aortic dF/dt. Two hours after injection of Ucn, coronary blood flow exhibited a significant increase from control, and this was associated with a rise in coronary conductance. The changes in arterial pressure, heart rate, cardiac output, coronary contractility, blood flow, and conductance were all dose dependent. The onset of the cardiac inotropic effect of Ucn, before any change in blood pressure or central venous pressure, suggests that the action of Ucn to increase cardiac contractility in sheep is not a reflex response to changes in cardiac preload or afterload.
The increase in coronary arterial blood flow and conductance in sheep demonstrates that Ucn has a coronary vasodilator action. Whether this is a direct action of Ucn to produce vascular relaxation as suggested by the in vitro study reported for Ucn (12) 
Interestingly, we found that in sheep the Ucn-induced cardiac actions were of extensive duration. The cardiac inotropic and coronary vasodilator actions of Ucn were still maximal 4 h after a bolus injection of Ucn, with the peak response reached ~2 h after injection, plateauing after this time at maximal change. In a group of sheep monitored continuously for 3 days after Ucn injection, we observed that cardiac contractility remained significantly elevated for up to 24 h after injection, whereas other hemodynamic variables had returned to control values within 14 h. There are no reports of such a long duration of inotropic action for any peptide, and the data suggest that once Ucn has bound to receptors mediating cardiovascular changes it can maintain binding and signaling for extremely long periods or persistently stimulate release of endogenous inotropic factors. When comparing the inotropic activity of Ucn with another peptide known to increase cardiac contractility, we have shown that the vasodilator adrenomedullin produces a 15% increase in aortic dF/dt in sheep. Ucn given at equimolar doses increased aortic dF/dt by almost 120%, indicating that Ucn is an extremely potent cardiac inotrope in conscious sheep.
It was also observed that the CRF antagonist α-helical CRF-(9-41) could abolish the cardiovascular changes produced by Ucn in sheep. Because we observed complete inhibition of the cardiovascular changes produced by Ucn with a dose ratio of α-helical CRF-(9-41) to Ucn of 10:1, this suggested that these changes are more likely to be mediated via CRF-R2, since this antagonist is reported to be more selective for CRF-R2 and much higher dose ratios of antagonist to agonist are needed to significantly block CRF-R1.
We have recently assessed the ability of Ucn to produce cardiac actions in the absence of an intact autonomic nervous system. These experiments were designed to determine whether Ucn may be acting directly on the heart or via a secondary mechanism, possibly via actions on circumventricular organs in the brain or on the peripheral nervous system, to activate sympathetic outflow to the heart and vasculature. This study demonstrated that ganglion blockade did not prevent the cardiac effects of Ucn. The Ucn-induced increases in cardiac output and heart rate, and the striking increase in cardiac contractility, were similar in intact and ganglion-blocked sheep. This indicates that these actions of Ucn were not mediated by the autonomic nervous system, and it is likely that they are mediated by a direct action of Ucn on the heart, possibly via binding to CRF-R2β receptors.
Other actions of Ucn
Synthetic Ucn can stimulate release of ACTH to a greater extent than CRF from isolated rat pituitary cells as well as in vivo in conscious rats (15) and sheep (9) . This is consistent with the peptide's ability to bind and activate CRF-R1 expressed by corticotropes within the anterior pituitary (15) . Interestingly, it appears that although exogenous Ucn is a potent stimulator of ACTH release, endogenous Ucn may not Ucn also has actions that may play an important role in cardiac protection. Natriuretic peptides are released from the heart in response to atrial and ventricular stretch, and their levels are increased in heart failure, during which it is proposed that they have a protective action. Ucn stimulated secretion of atrial and brain natriuretic peptides in cultured neonatal rat myocytes by an action on CRF-R2. Furthermore, Ucn has been shown to have protective actions in a rat cardiac myocyte cell line. Expression of Ucn mRNA was increased after thermal injury, and Ucn was shown to protect cardiac myocytes from cell death induced by hypoxia (7), indicating that Ucn may act as an endogenous cardioprotective agent. In response to an injury, such as a myocardial infarction, Ucn could act to cause the release of natriuretic peptides and other locally released mediators, which would have a protective role both systemically and at a local level. However, whether these mechanisms play an important role in vivo remains to be established.
It is well accepted that CRF can have marked effects on behavior to suppress appetite, stimulate arousal, and increase performance in various memory and learning exercises, and at higher doses it can increase emotionality, leading to fear, anxiety, and depression-like effects in a variety of species. Spina and co-workers (11) have demonstrated that Ucn, when given intracerbroventricularly to rats, can strongly suppress food and water intake in both food-deprived and freely feeding states. This appetite-suppressing action of Ucn was significantly more potent than that for CRF. Interestingly, in this study, Ucn did not produce any anxiogenic-like behavior when rats were tested in an emotionality test (elevated plus maze), a test in rats known to be sensitive to CRF. Significant behavioral actions were observed with intravenous Ucn administration in sheep, particularly at higher doses (9) . Ucn markedly suppressed appetite for food and water in sheep for at least 12 h after the normal time of feeding; however, the animals did not appear anxious or stressed. Significant levels of CRF-R2 expression are seen within the gastrointestinal tract, and high levels of Ucn mRNA are also seen at several important junctions along the gastrointestinal tract. Consistent with this, Ucn may act directly on the gut to inhibit gastric motility, in combination with central actions to suppress feeding behavior and autonomic control of gastric emptying. These actions of Ucn contribute to the peptide's overall action to regulate caloric intake (Fig. 4) .
Several of the other localized actions of CRF on inflammation, metabolism, respiration, and the immune system may be mimicked by Ucn when examined in forthcoming studies, especially in regions or tissues in which there are high levels of CRF-R2 expression. Of significance, Ucn exhibits high affinity for the CRF binding protein (CRF-BP), which may modulate actions of Ucn within the brain and periphery.
Future directions
Ucn is now emerging as a potential hormone involved in cardiovascular control and may be the "missing link" with regard to some peripheral actions of CRF. Increasing evidence, based on CRF/Ucn receptor expression, Ucn peptide expression, and Ucn physiology, indicates that this peptide may be present in significant concentrations and at relevant sites to control a number of local physiological systems. In addition, Ucn has specific actions within the central nervous system to regulate behavior, blood pressure, and hormonal release from the pituitary. The marked and persistent cardiovascular, hormonal, and behavioral actions of Ucn following intravenous administration are intriguing. In particular, the cardiac inotropic action of Ucn is unique with regard to its potency and duration of action when compared with other cardioactive peptides, and this appears to be the primary cardiovascular action of this peptide in sheep. Whether this potent inotropic action of Ucn may prove useful in developing analogs/therapeutics for treatment of myocardial infarction or congestive heart failure depends on confirmatory studies examining the cardiovascular actions of this peptide in primates and humans. Of high relevance, understanding the control of Ucn secretion into the circulation and within peripheral tissues will provide answers to the physiological and pathological significance of systemic Ucn.
Overall, it is now evident that Ucn plays a significant role in the control of cardiac function and peripheral hemodynamics and may be one of the primary factors involved in the cardiovascular response to a stressful stimulus. To what extent these marked cardiovascular changes of Ucn impact on other actions, such as slowing of gastric emptying, suppression of inflammation, and release of ACTH/cortisol, remains to be elucidated.
T he role of myoglobin as an oxygen store is well established. In terrestrial mammals, it compensates for the disadvantage of a reduced blood flow in heart and skeletal muscle during contraction. In aquatic mammals, which are characterized by markedly higher myoglobin concentrations than terrestrial mammals, it serves as an oxygen reservoir during the time ventilation ceases.
The physiological significance of myoglobin-facilitated oxygen diffusion, i.e., reversible combination of myoglobin with oxygen and translational diffusion of oxymyoglobin molecules, has been a matter of controversy since Wittenberg (15) first reported evidence for it. Several approaches have been used to explore the physiological importance of this mechanism of intracellular oxygen transport. It has been attempted to experimentally evaluate its role in isolated cells, in isolated muscle tissue, and in vivo, both directly by chemically or genetically abolishing myoglobin function in the cell and observing the consequences for oxygen consumption or for physical performance and indirectly by determining the oxygen conductance of muscle tissue from measurements of oxygen consumption and intracellular PO 2 gradients. Theoretically, the problem was assessed in numerous model calculations, all of which until recently suffered from the lack of a reliable value for the intracellular diffusivity of myoglobin. We summarize here the results of these studies, and, taking into account our data on the intracellular myoglobin diffusivity, reevaluate the physiological role of myoglobinfacilitated oxygen transport in heavily exercising muscles by applying a modified Krogh cylinder model (6) .
Evidence for facilitated oxygen diffusion from abolishing myoglobin function
In an earlier study (12) , we concluded that all experimental studies reporting evidence for a significant contribution of myoglobin-facilitated diffusion to total intracellular oxygen transport exhibit experimental insufficiencies. One group blocked myoglobin function with carbon monoxide but chose an experimental setup in which severe hypoxia or anoxia was present in the muscle tissue investigated. Therefore, these results essentially show that myoglobin-facilitated oxygen diffusion plays a role at unphysiologically low PO 2 ( Table 1) . Other groups used myoglobin-blocking reagents that are known to cause severe side effects (Table 1) . Thus, besides the desired inhibitory effect on myoglobin, substantial poisoning effects on other proteins involved in cellular respiration cannot be excluded in these studies. Furthermore, blocking of myoglobin not only abolishes facilitated oxygen diffusion but also prevents the storage of oxygen. In rhythmically contracting muscles, the lack of an oxygen store may cause reduced performance, just as a lower oxygen conductance does. Therefore, from these experimental approaches no clear evidence can be derived that, under physiological conditions, the working muscle significantly benefits from myoglobin-facilitated oxygen diffusion.
Recently, two groups who performed a knockout of the myoglobin gene in mice have arrived at contradictory results (Table 1) . Garry et al. (2) reported that myoglobin-free mice exhibit normal exercise capacity and show no striking changes in muscle tissue parameters compared with normal mice. Gödecke et al. (5) also did not observe any physical disadvantage of myoglobin-free mice but found a 30% higher capillary density of the heart and, in beating Langendorff hearts perfused with hemoglobin-free solution, a 25% higher maximal coronary blood flow. This flow may be considerably less elevated in beating myoglobin-free hearts in vivo when perfused with blood.
In these knockout mice, the lack of myoglobin has obviously induced compensatory mechanisms during ontogenesis, but in our opinion it is not clear whether these mechanisms are required to compensate for the absence of the storage function of myoglobin or to compensate for a lack of myoglobin-facilitated oxygen diffusion. At a given oxygen consumption, a higher blood flow as well as a higher capillary density increases the PO 2 of the tissue and hence increases the concentration of dissolved oxygen. This additional amount of oxygen stored in the heart has been calculated to be large enough to ensure a sufficient oxygen supply during systolic cessation of blood flow in the myoglobin-free rat heart.
Evidence for facilitated oxygen diffusion from measuring intracellular MbSO 2 gradients
Indirect evidence for a substantial role of myoglobinfacilitated oxygen transport in working muscle has been
